BR112022011321A2 - Compostos, polímeros, dispositivos e seus usos - Google Patents

Compostos, polímeros, dispositivos e seus usos

Info

Publication number
BR112022011321A2
BR112022011321A2 BR112022011321A BR112022011321A BR112022011321A2 BR 112022011321 A2 BR112022011321 A2 BR 112022011321A2 BR 112022011321 A BR112022011321 A BR 112022011321A BR 112022011321 A BR112022011321 A BR 112022011321A BR 112022011321 A2 BR112022011321 A2 BR 112022011321A2
Authority
BR
Brazil
Prior art keywords
compounds
polymers
devices
formula
methods
Prior art date
Application number
BR112022011321A
Other languages
English (en)
Inventor
Heidebrecht Richard
Bourque Elyse
P Hencken Christopher
Original Assignee
Sigilon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigilon Therapeutics Inc filed Critical Sigilon Therapeutics Inc
Publication of BR112022011321A2 publication Critical patent/BR112022011321A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Polyamides (AREA)

Abstract

COMPOSTOS, POLÍMEROS, DISPOSITIVOS E SEUS USOS. São descritos aqui compostos da Fórmula (I), polímeros e elementos implantáveis compreendendo compostos da Fórmula (II) e composições e métodos de seu uso. Em particular, os compostos, polímeros modificados, elementos implantáveis e composições relacionadas podem ser usados em métodos para a prevenção e tratamento de uma doença, disfunção ou condição em um sujeito.
BR112022011321A 2019-12-13 2020-12-11 Compostos, polímeros, dispositivos e seus usos BR112022011321A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947951P 2019-12-13 2019-12-13
PCT/US2020/064661 WO2021119522A1 (en) 2019-12-13 2020-12-11 Compounds, polymers, devices, and uses thereof

Publications (1)

Publication Number Publication Date
BR112022011321A2 true BR112022011321A2 (pt) 2022-08-23

Family

ID=76330636

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011321A BR112022011321A2 (pt) 2019-12-13 2020-12-11 Compostos, polímeros, dispositivos e seus usos

Country Status (11)

Country Link
US (1) US20230045277A1 (pt)
EP (1) EP4072545A4 (pt)
JP (1) JP2023506786A (pt)
KR (1) KR20220115592A (pt)
CN (1) CN114901276A (pt)
AU (1) AU2020401369A1 (pt)
BR (1) BR112022011321A2 (pt)
CA (1) CA3163491A1 (pt)
IL (1) IL293826A (pt)
MX (1) MX2022007285A (pt)
WO (1) WO2021119522A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020003351A (es) * 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Metodos, composiciones y elementos implantables que comprenden celulas activas.
WO2023129726A2 (en) * 2021-12-30 2023-07-06 Sigilon Therapeutics, Inc. Modified polysaccharide polymers and related compositions and methods thereof
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
WO2023235884A1 (en) 2022-06-03 2023-12-07 Flagship Pioneering Innovations Vi, Llc Compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019006712A2 (pt) * 2016-10-03 2019-06-25 Sigilon Therapeutics Inc composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
EP3584318A4 (en) * 2017-02-16 2020-11-25 Ajinomoto Co., Inc. POLYMER BALL
US20180353650A1 (en) * 2017-06-13 2018-12-13 Massachusetts Institute Of Technology Biocompatible microfabricated macrodevices for transplanting cells
MX2020003351A (es) * 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Metodos, composiciones y elementos implantables que comprenden celulas activas.
IL277713B1 (en) * 2018-04-04 2024-05-01 Sigilon Therapeutics Inc Implantable particles and related methods

Also Published As

Publication number Publication date
IL293826A (en) 2022-08-01
KR20220115592A (ko) 2022-08-17
MX2022007285A (es) 2022-08-04
WO2021119522A1 (en) 2021-06-17
CA3163491A1 (en) 2021-06-17
CN114901276A (zh) 2022-08-12
EP4072545A1 (en) 2022-10-19
EP4072545A4 (en) 2024-01-24
AU2020401369A1 (en) 2022-06-09
JP2023506786A (ja) 2023-02-20
US20230045277A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
BR112022011321A2 (pt) Compostos, polímeros, dispositivos e seus usos
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
BR112022002580A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112018000808A2 (pt) compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
EA202190377A1 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
BR112018074450A2 (pt) composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
BR112022001415A2 (pt) Agentes interleucina-2 e os usos dos mesmos
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112022007612A2 (pt) Inibidores de raf quinases
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
BR112017007708A2 (pt) composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
CO2022000481A2 (es) Inhibidores de enzimas
MX2021001612A (es) Compuestos utiles en terapia del vih.
CL2020002833A1 (es) Métodos para tratar cáncer
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença